RT Journal Article
SR Electronic
T1 Clinical Response to fMRI-guided Compared to Non-Image Guided rTMS in Depression and PTSD: A Randomized Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.29.24311191
DO 10.1101/2024.07.29.24311191
A1 Oathes, Desmond J.
A1 Gonzalez, Almaris Figueroa
A1 Grier, Julie
A1 Blaine, Camille
A1 Garcia, Sarai D.
A1 Linn, Kristin A.
YR 2024
UL http://medrxiv.org/content/early/2024/07/31/2024.07.29.24311191.abstract
AB Background Image-guided brain stimulation is hypothesized to enhance clinical outcomes but head-to-head comparisons favoring image-guidance are so far lacking.Methods PTSD/MDD patients were randomized (N=51) to a two-condition sequence in a two period cross-over design. For the first condition, patients were randomized to 10-session rTMS treatment to either a subgenual cingulate (sgACC) functional connectivity cortical target (fMRI-guided) or standard scalp-based target. Additionally, patients were randomized to either watch a nature video or perform a demanding cognitive task with rTMS administration. Patients crossed over to the two conditions not received in period one. rTMS was delivered in an intermittent theta burst (iTBS) pattern with 2400 pulses per session. Among N=49 patients analyzed, 60% identified as female and average age was 34.Results Compared with the scalp-based target, fMRI-guided rTMS was superior in improving depression symptoms (F(1,43.92)=5.933, p=0.019) as well as PTSD hyperarousal (F(1,40.78)=5.076, p=0.030). The median level of symptom change for fMRI-guided targets exceeded 60% improvement across both scales. Symptom improvements at 6-mo follow-up were durable and both favored fMRI-guidance. For patients reporting symptoms at this timepoint, depression improved by 70% (N13); the PCL improved by 69% with Hyperarousal (N14) and Avoidance (N12) subscales improving by 78% and 79%, respectively, for the fMRI-guided target.Conclusions We demonstrated preliminary evidence for the clinical superiority of a new fMRI-guided target which should be followed up with larger comparative effectiveness studies that include imaging and clinical outcomes.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03114891Funding StatementCureAccelerator Repurposing Award from Cures Within Reach and the Kahlert Foundation (DJO).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the University of Pennsylvania Perelman School of Medicine gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes